xoma 358
mAbexperimental
Clinical trial activity
8 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
1
Earliest trial started Jul 1, 2006 (NCT00439179)
Timeline
Indications
Approved for
Mechanism of action
- Insulin receptorINHIBITOR
INSR inhibitor
- InsulinINHIBITOR
INS inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- xoma 358
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04538989 | Phase 2 | Dec 31, 2020 | Rezolute |
| NCT02772718 | Phase 2 | Apr 1, 2016 | Xoma |
| NCT02604485 | Phase 2 | Oct 1, 2015 | Xoma |
| NCT01967758 | Phase 1 | Oct 1, 2013 | Aduro BioTech, Providence Health & Services |
| NCT01516047 | Phase 1 | Jan 1, 2012 | Johnson and Johnson |
| NCT01400555 | Phase 1 | Sep 1, 2011 | Cougar Biotechnology |
| NCT00777764 | Phase 4 | Aug 1, 2008 | Genentech |
| NCT00439179 | Phase 1 | Jul 1, 2006 | Brown University, GlaxoSmithKline |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xoma | For profit | 2 | 2 | 1 | 2015 |
| Aduro BioTech | For profit | 1 | 0 | 1 | 2013 |
| Brown University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Cougar Biotechnology | For profit | 1 | 1 | 1 | 2011 |
| Genentech | For profit | 1 | 1 | 1 | 2008 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2006 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2012 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Rezolute | For profit | 1 | 1 | 1 | 2020 |
9 organizations
Page 1 / 1